Proteasome inhibition and Parkinson's disease modeling

Annals of Neurology

Volumn 60, Issue 2, 2006, Pages 260-264

  Bové, Jordi ^a   Zhou, Chun ^a   Jackson Lewis, Vernice ^a   Taylor, Julie ^b   Chu, Yaping ^c   Rideout, Hardy J ^a   Wu, Du Chu ^a   Kordower, Jeffrey H ^c   Petrucelli, Leonard ^b   Przedborski, Serge ^a,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MAYO CLINIC   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; PROTEASOME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INTERNEURON; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REPRODUCIBILITY;

ANIMALS; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; OLIGOPEPTIDES; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE;

EID: 33746850545     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20937     Document Type: Article

References (20)

1. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
2. Braak H, Braak E, Yilmazer D, et al. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl 1995; 46:15-31.
3. McNaught KS, Perl DP, Brownell AL, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-162.
4. Tieu K, Perier C, Caspersen C, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest 2003;112:892-901.
5. Przedborski S, Levivier M, Jiang H, et al. Dose-dependent lesions of the dopaminergic nigrostnatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995; 67:631-647.
6. Muthane U, Ramsay KA, Jiang H, et al. Differences in nigral neuron number and sensitivity to 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1mice. Exp Neurol 1994;126:195-204.
7. Liberatore G, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999; 5:1403-1409.
8. Kostic V, Jackson-Lewis V, De Bilbao F, et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997;277:559-562.
9. Vila M, Vukosavic S, Jackson-Lewis V, et al. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000;74:721-729.
10. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001;292:1552-1555.
11. Zhou C, Emadi S, Sierks MR, et al. A human single-chain Fv inrrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 2004;10:1023-1031.
12. Borchelt DR, Davis J, Fischer M, et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal 1996;13:159-163.
13. Petrucelli L, O'Farrell C, Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002;36:1007-1019.
14. McNaught K, Olanow CW. The proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol 2006;60:243-247.
15. Zeng BY, Bukhatwa S, Hikima A, et al. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol 2006;60:248-252.
16. Schapira AHV, Cleeter MWJ, Muddle JR, et al. Proteosomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 2006;60:253-255.
17. Manning-Bog AB, Reaney SH, Chou VP, et al. Lack of nigrostriatal pathology in a rat model of proteosome inhibition. Ann Neurol 2006;60:256-260.
18. Kordower JH, Kanaan NM, Chu Y, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 2006;60:264-268.
19. Lang AE, Beal MF. The proteosomal inhibition model of Parkinson's disease: "boon or busr"? Ann Neurol 2006;60:158-161.
20. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-1306.